MCL1 and lymphoma: Several lines of in vitro evidence suggest that sorafenib might have a role in the treatment of lymphomas by overcoming the cytoprotective effects of ERK, and Mcl-1 and eventually targeting oncogenic signaling pathways driving lymphomagenesis [19]–[23].